Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in HER2-Positive Stage IV Breast Cancer
NCT00041067Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Sep 2002
- Primary completion
- Jan 2008
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab, docetaxel, vinorelbine and filgrastim in breast cancer, sponsored by SWOG Cancer Research Network. Primary endpoint: Survival at 1 Year. Started Sep 2002; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00041067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00041067.